Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Blood|October 31, 2018
Subclonal TP53 copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic ProfilingGiuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Blood Cancer Journal|April 20, 2021
Germline variants at SOHLH2 influence multiple myeloma riskLaura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Pageof 6